Climb Bio (CLYM) director Judith Dunn receives 40,000 stock options grant

Rhea-AI Filing Summary

Climb Bio, Inc. director Judith Dunn received a grant of stock options representing the right to buy 40,000 shares of common stock. The options have an exercise price of $10.55 per share and expire on June 4, 2036. The 40,000 underlying shares will vest on the earlier of June 5, 2027 or the date immediately prior to the next annual meeting of stockholders, as long as she continues to serve through that date. Following this grant, she holds stock options for 40,000 shares directly.

Insider Trade Summary

1 transaction reported

Mixed 1 txn

Insider Dunn Judith

Role null

Type	Security	Shares	Price	Value
Grant/Award	Stock Option (Right to Buy)	40,000	$0.00	--

Holdings After Transaction: Stock Option (Right to Buy) — 40,000 shares (Direct, null)

Footnotes (1)

1. [object Object]

Key Figures

Options granted: 40,000 options Exercise price: $10.55 per share Expiration date: June 4, 2036 +2 more

5 metrics

Options granted 40,000 options Stock Option (Right to Buy) granted to director Judith Dunn

Exercise price $10.55 per share Exercise price of stock options for Climb Bio common stock

Expiration date June 4, 2036 Expiration of stock option grant

Underlying shares 40,000 shares Common stock underlying the stock option grant

Post-grant holdings 40,000 options Total stock options held directly after the transaction

Key Terms

Stock Option (Right to Buy), exercise price, expiration date, annual meeting of stockholders

4 terms

Stock Option (Right to Buy) financial

"security_title: Stock Option (Right to Buy)"

exercise price financial

"conversion_or_exercise_price: 10.5500"

The exercise price is the fixed amount at which you can buy or sell an asset, like a stock, when using an options contract. It matters because it helps determine whether exercising the option will be profitable or not, depending on the current market price. Think of it as the set price you agree on today to buy or sell later.

expiration date financial

"expiration_date: 2036-06-04T00:00:00.000Z"

The expiration date is the deadline after which a financial contract, such as an option or a futures agreement, is no longer valid or can be exercised. It matters to investors because it determines the timeframe during which they can take action or benefit from the contract, similar to how a coupon or a food item has a limited period of usefulness. Once the expiration date passes, the contract loses its value or ability to be used.

annual meeting of stockholders financial

"earlier of June 5, 2027 or the date immediately prior to the date of the next annual meeting of stockholders"

See more from StockTitan in Google Search and AI answers. Adds StockTitan as a preferred source · opens Google

Add on Google Not now

Form 4 Insider Transactions: What Each Field Means →

SEC Form 4

FORM 4

UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934
or Section 30(h) of the Investment Company Act of 1940

OMB APPROVAL

OMB Number:			3235-0287
Estimated average burden
hours per response:			0.5

Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).

Check this box to indicate that a transaction was made pursuant to a contract, instruction or written plan for the purchase or sale of equity securities of the issuer that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c). See Instruction 10.

1. Name and Address of Reporting Person^*

Dunn Judith

(Last) (First) (Middle)

C/O CLIMB BIO, INC.

20 WILLIAM STREET, SUITE 145

(Street)

WELLESLEY HILLS MASSACHUSETTS 02481

(City) (State) (Zip)

UNITED STATES

(Country)

2. Issuer Name and Ticker or Trading Symbol
Climb Bio, Inc. [ CLYM ]

5. Relationship of Reporting Person(s) to Issuer
(Check all applicable)

X	Director		10% Owner
	Officer (give title below)		Other (specify below)

2a. Foreign Trading Symbol

3. Date of Earliest Transaction (Month/Day/Year)
06/05/2026

6. Individual or Joint/Group Filing (Check Applicable Line)

X	Form filed by One Reporting Person
	Form filed by More than One Reporting Person

4. If Amendment, Date of Original Filed (Month/Day/Year)

Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned
1. Title of Security (Instr. 3)	2. Transaction Date (Month/Day/Year)	2A. Deemed Execution Date, if any (Month/Day/Year)	3. Transaction Code (Instr. 8)		4. Securities Acquired (A) or Disposed Of (D) (Instr. 3, 4 and 5)			5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4)	6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	7. Nature of Indirect Beneficial Ownership (Instr. 4)
			Code	V	Amount	(A) or (D)	Price

Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)
1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	3A. Deemed Execution Date, if any (Month/Day/Year)	4. Transaction Code (Instr. 8)		5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5)		6. Date Exercisable and Expiration Date (Month/Day/Year)		7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4)		8. Price of Derivative Security (Instr. 5)	9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4)	10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	11. Nature of Indirect Beneficial Ownership (Instr. 4)
				Code	V	(A)	(D)	Date Exercisable	Expiration Date	Title	Amount or Number of Shares
Stock Option (Right to Buy)	$10.55	06/05/2026		A		40,000		(1)	06/04/2036	Common Stock	40,000	$0	40,000	D

Explanation of Responses:

1. The shares subject to the option will vest on the earlier of June 5, 2027 or the date immediately prior to the date of the next annual meeting of stockholders, subject to the reporting person's continued service through such date.

	Chandra Adams, as Attorney-in-Fact	06/08/2026
	** Signature of Reporting Person	Date
Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
* If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.
* Form 4: SEC 1474 (03-26)

FAQ

What did Climb Bio (CLYM) director Judith Dunn report on this Form 4?

Judith Dunn reported receiving a grant of stock options for 40,000 shares of Climb Bio common stock. These options are compensation-related and give her the right to buy shares at a fixed exercise price if they vest.

How many Climb Bio (CLYM) stock options did Judith Dunn receive and at what price?

She received stock options covering 40,000 shares of Climb Bio common stock with an exercise price of $10.55 per share. This price is the amount she would pay per share if she chooses to exercise the options in the future.

When do Judith Dunn’s Climb Bio (CLYM) stock options vest?

The options will vest on the earlier of June 5, 2027 or the date immediately before Climb Bio’s next annual stockholder meeting. Vesting is conditional on her continued service with the company through that applicable date.

What is the expiration date of Judith Dunn’s Climb Bio (CLYM) stock options?

The options expire on June 4, 2036. After this expiration date, any unexercised options will lapse, meaning she would no longer be able to purchase Climb Bio shares under this specific option grant.

How many Climb Bio (CLYM) options does Judith Dunn hold after this grant?

After this transaction, she holds stock options for 40,000 shares of Climb Bio common stock directly. The filing does not list additional derivative positions beyond this grant in the derivative position summary.